• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » NuVasive swings to Q4, 2011 red | Earnings Roundup

NuVasive swings to Q4, 2011 red | Earnings Roundup

February 24, 2012 By MassDevice staff

NuVasive

NuVasive (NSDQ:NUVA) swung to red for the 4th quarter and full-year 2011, largely on the back of an $18.2 million writedown of intangible assets.

The San Diego-based spinal implant maker posted a loss of $10.0 million, or 24 cents per share, on sales of $150.2 million for the 3 months ended Dec. 31, 2012. That’s a top-line gain of 16.2% compared with Q4 2010, when NuVasive posted profits of $61.9 million, or $1.39 EPS.

For the full year, the company reported losses of $69.8 million, or $1.73 per share, on sales of $540.5 million, a revenue increase of $13.0% compared with the prior year, when NuVasive reported profits of $78.3 million, or $1.85 EPS, on sales of $478.2 million.

Excluding 1-time items, adjusted earnings for the 4th quarter reached $11.4 million, or 27 cents per share. Adjusted earnings for the full year were $43.9 million, or $1.07 per share.

“Our financial performance in 2011 attests to the exceptional execution of our market-share taking strategy, which drove revenue growth of 13% within a challenged US spine market that did not grow," chairman & CEO Alex Lukianov said in prepared remarks. "As the spine market shifts toward more minimally invasive procedures, NuVasive is ready to further penetrate the market and we expect to again lead the industry in market share gains in 2012. Normalized for the full-year impacts of certain 2011 events, we expect to improve the operating profile of our business in 2012, with a pre-tax earnings growth rate nearly 2 times the rate of revenue growth. Through the breadth of our procedural offerings, increased global expansion, and continued focus on superior clinical outcomes, we are well positioned to achieve our longer-term goal of becoming the #3 company in spine, with $1 billion in revenue and a greatly improved profitability profile.”

NuVasive said it expects to post revenues of about $615 million this year, with EPS of 9 cents and adjusted EPS of 93 cents.

Lukianov told analysts on a conference call that the company is eager to move on with an appeal of its $101.2 million loss to Medtronic (NYSE:MDT) in a patent infringement care last year.

"Things have largely gone as anticipated on our end, so we can’t really speculate as to how of that is all going to shake out," Lukianov said. "But were optimistic and excited to get to the point of starting the appellate process."

NUVA shares were trading at $15.01 as of about 12:20 today, down 2.9% on the day.

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

 CardioNet soars on Street-beating Q4 results
Cost-cutting efforts helped CardioNet (NSDQ:BEAT) top Wall Street’s expectations for the 4th quarter, despite slipping sales for its mobile cardiac outpatient telemetry systems.

The Conshohocken, Pa.-based heart monitor maker posted losses of $49.8 million, or 2.03 cents per share, on sales of $26.8 million for the 3 months ended Dec. 31., and losses of $61.4 million, or $2.51, on losses of $119 million for full-year 2011.

That compares with losses of $26.8 million, or 20 cents per share, on sales of $28.7 million during the 4th quarter in 2010, and losses of $19.9 million, or 82 cents per share, on sales of $199.9 million during for the full year 2010. Read more

 Volcano beats The Street but guides low for 2012

Volcano Corp. (NSDQ:VOLC) blew away analysts’ expectations for the 4th quarter and 2011, but lost some love on Wall Street over its low guidance for 2012.

The San Diego-based cardiac monitoring company posted profits of $29.4 million, or 54 cents per diluted share, on sales of $92.7 million for the 3 months ended Dec. 31 and full-year profits of $38.1 million, or 70 cents per diluted share, on sales of $343.5 million.

That compares with Q4 2010 losses of $1.7 million, or 3 cents per share, on sales of $81.2 million and profits of $5.2 million, or 10 cents per diluted share, on sales of $185.3 million for the full year. Read more

 Teleflex tanks on missed Q4, 2011 earnings
Teleflex shares (NYSE:TFX) took a hit this morning after the medical device maker missed Wall Street’s profit expectations, despite raising both its top and bottom lines.

The Limerick, Pa.-based company posted profits of $167.8 million, or $1.02 per diluted share, on sales of $411.7 million during the 3 months ended Dec. 31, 2011. That’s a bottom-line gain of 107% and a top-line addition of 6.6%, compared with profits of $81.1 million, or 33 cents diluted EPS, on sales of $386.3 million for Q4 2010.

For the full year, Teleflex posted profits of $323.3 million, or $2.96 diluted EPS, on sales of $1.53 billion, up 60.8% and 6.7%, respectively, compared with profits of $201.1 million, or $2.21 diluted EPS, on sales of $1.43 billion during 2010.
Read more

 Theragenics sales, earning slide in Q4
Theragenics Corp. (NYSE:TGX) saw shrinking sales in the in the 3 months ended Dec. 31, 2011, but full-year earning soared for 2011.

The Buford, Ga.-based -based device maker posted profits of $280,000, or 1 cent per diluted share, on sales of $19.9 million for its 4th quarter and profits of $3.1 million, or 9 cents per diluted share, on sales of $82.7 million for the full year 2011.

That compares with Q4 2010 profits of $373,000, or 1 cent per diluted share, on sales of $20.7 million and full year 2010 profits of $2.1 million, or 6 cent per diluted share, on sales of $82.2 million. Read more

 ArthroCare slips into the red
ArthroCare Corp. (NSDQ:ARTC) slipped into the red in the 4th quarter and full year 2011.

The Austin, Texas-based company posted losses of $29.3 million, or $1.06 per share, on sales of $92.4 million for the 3 months ended Dec. 31, 2011 and losses of $4.3 million, or 23 cents per share, on sales of $345.9 million for the full year 2011.

That compares with Q4 2010 profits of $10.1 million, or 30 cents per diluted share, on sales of $92.6 million and full-year 2010 profits of $33.8 million, or $1.03 per diluted share, on sales of $355.4 million. Read more

 VirtualScopics breaks out of the red in 2011
VirtualScopics (NSDQ:VSCP) broke into the black 2011.

The company posted profits of $$1.1 million on sales of $3.1 million for the 3 months ended Dec. 31, 2011 and profits of $654,000, or 2 cents per diluted share, on sales of $13.1 million for the full year.

That compares with Q4 2010 losses of $1.6 million, or 6 cents per share, on sales of $3.2 million and full-year 2010 losses of $800,000, or 3 cents per share, on sales of $12.3 million. Read more

 Digirad widens losses in Q4
Digirad (NSDQ:DRAD) sank deeper into the red in its 4th quarter of 2011 but narrowed losses for the full year.

The Poway, Calif.-based company posted losses of $2.8 million, or 15 cents per share, on sales of $11.9 million for the 3 months ended Dec. 31, 2011, and losses of $3.3 million, or 18 cents per share, on sales of $53.7 million for the full year.

That compares with Q4 2010 losses of $559,000, or 3 cents per share, on sales of $14.7 and full-year 2010 losses of $6.2 million, or 33 cents per share, on sales of $56.2 million. Read more

 Fresenius sales, earning rise in Q4, full year 2010
Fresenius Medical Care (NYSE:FMS) posted strong growth in sales and earning for the 4th quarter and full year 2010.

The device company posted profits of $310,000, or $1.02 per diluted share, on sales of $3.3 million for the 3 months ended Dec. 31, 2011 and full-year profits of $1.1 million, or $3.54 per diluted share, on sales of $12.8 million.

That compares with Q4 2010 profits of $271,000, or 90 cents diluted share, on sales of $3.2 million and full year 2010 profits of $979,000, or $3.25 per diluted share, on sales of $12.1 million. Read more

 Symmetry slips into the red in Q4
Symmetry Medical (NYSE:SMA)  saw slipped into the red in its 4th quarter 2011.

The Warsaw, Ind.-based orthopedics company posted losses of $3.2 million, or 9 cents per share, on sales of $84.5 million for the 3 months ended Dec. 31, 2011 and profits of $2.9 million, or 8 cents per diluted share, on sales of $359 million for the full year.

That compares with Q4 2010 profits of $4.3 million, or 12 cents per diluted share, on sales of $96 million and full year 2010 profits of $14 million, or 39 cents per diluted share, on sales of $361 million. Read more

 Endologix posts losses for 4th quarter, full year 2011
Endologix Inc. (NSDQ:ELGX) sank into the red in the 4th quarter and full year 2011.

The Irvine, Calif.-based company posted losses of $3.7 million, or 6 cents per share, on sales of $23.4 million for the 3 months ended Dec. 31, 2011 and losses of $28.7 million, or 51 cents per share, on sales of $83.4 million for the full year.

That compares with Q4 2010 profits of $11.7 million, or 22 cents per diluted share, on sales of $19.2 million and full-year 2010 profits of $10.7 million, or 21 cents per diluted share, on sales of $67.3 million. Read more

 Hansen posts narrowed losses
Hansen Medical Inc. (NSDQ:HNSN) narrowed losses in its 4th quarter and full year of 2010.

The device maker posted losses of $9.5 million, or 16 cents per share, on sales of $6.2 million for the 3 months ended Dec. 31, 2011 and losses of $16.7 million, or 30 cents per share, on sales of $22.1 million for the full year.

That compares with Q4 2010 losses of $11 million, or 20 cents per share, on sales of $3.5 million and full-year 2010 losses of $37.9 million, or 78 cents per share, on sales of $16.6 million. Read more

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: ArthroCare Corp., CardioNet Inc., Digirad Corp., Endologix, Fresenius, Hansen Medical Inc., Nuvasive, Q4, Symmetry Medical Inc., Teleflex, Theragenics Corp., VirtualScopics Inc., Volcano Corp.

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS